Latest profit margin for Genmab A/S: 9.74% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
As of the most recent data (June 2026), GE9.F shows a profit margin of 9.74%. That compares with 41.42% in the prior-year period — down 76.5% year over year. That is below the Healthcare sector average of 10.58%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, GE9.F's profit margin is now 9.74% (was 41.42%) — a 76.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Genmab A/S is outperforming or lagging.
The Healthcare sector average profit margin is about 10.58%. Genmab A/S is at 9.74%, which is lower that average. That is roughly 8.0% below the sector mean. Use the comparison chart on this page to see how GE9.F stacks up against individual peers as well.
That compares with 41.42% in the prior-year period — down 76.5% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Genmab A/S with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has Genmab A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 9.74%) with ownership activity and broader fundamentals.